For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study for Patients with Acute Myeloid Leukemia

Clinical Trial Title: 
A phase III randomized trial for patients with de novo AML using bortezomib and sorafenib (IND# I14480, NSC# 681239, NSC# 724772) for patients with high allelic ratio FLT3/ITD.
Clinical Trial Protocol ID: 
11062301-CAO I
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

To compare event free survival (EFS) and overall survival (OS) in patients with de nova acute myeloid leukemia (AML) without high allelic ratio FLT3/ITD+mutations who are randomized to standard therapy versus bortezomib/standard combination therapy.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are less that 30 years of age at the time of study enrollment.
  • Have been newly diagnosed with de novo acute myelogenous leukemia.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Pediatric Cancers and Blood Disorders
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane